Given the therapeutic value of monoclonal antibodies targeting the TNF-TNFR axis (infliximab and adalimumab) and a fusion protein (etanercept) that antagonizes TNF-α function in autoimmune inflammatory diseases, it has been proposed that modulating TNF-TNFR signaling, either with agonistic or neutralizing antibodies, may contribute to control tumor growth [17]. The gene discussed is TNFRSF1A; the disease is neoplasm.